Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2016', provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects
- The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 9
Therapeutics Development 10
Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview 10
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies 16
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development 18
3SBio Inc. 18
AkaRx Inc 19
Amgen Inc. 20
arGEN-X BV 21
Boehringer Ingelheim GmbH 22
Bristol-Myers Squibb Company 23
Genosco 24
Hansa Medical AB 25
Immunomedics, Inc. 26
Intas Pharmaceuticals Ltd. 27
Jiangsu Hengrui Medicine Co., Ltd. 28
Merck & Co., Inc. 29
Momenta Pharmaceuticals, Inc. 30
Novartis AG 31
Pfizer Inc. 32
PhytoHealth Corporation 33
Protalex, Inc. 34
Rigel Pharmaceuticals, Inc. 35
Shire Plc 36
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ARGX-113 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
avatrombopag - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
BI-655064 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
BMS-986004 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
eltrombopag olamine - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
eltrombopag olamine - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
fostamatinib disodium - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
GL-2045 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
GSK-2285921 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Hetrombopag Olamine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
M-281 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
MK-8723 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
PHN-013 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
PRTX-100 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
romiplostim - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
romiplostim biosimilar - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
SKIO-703 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
SM-101 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
thrombopoietin - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
veltuzumab - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects 94
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products 95
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones 96
Featured News & Press Releases 96
Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder 96
May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association 97
Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP 98
Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP 99
Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag 100
Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 100
Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 101
Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP 102
Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder 102
Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) 103
Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) 104
Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP 104
Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan 105
Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib 105
Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance 105
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

List of Tables

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016 10
Number of Products under Development by Companies, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by 3SBio Inc., H2 2016 18
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by AkaRx Inc, H2 2016 19
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Amgen Inc., H2 2016 20
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by arGEN-X BV, H2 2016 21
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 22
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Bristol-Myers Squibb Company, H2 2016 23
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Genosco, H2 2016 24
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Hansa Medical AB, H2 2016 25
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Immunomedics, Inc., H2 2016 26
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 27
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 28
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Merck & Co., Inc., H2 2016 29
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 30
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Novartis AG, H2 2016 31
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Pfizer Inc., H2 2016 32
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by PhytoHealth Corporation, H2 2016 33
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Protalex, Inc., H2 2016 34
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 35
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline by Shire Plc, H2 2016 36
Assessment by Monotherapy Products, H2 2016 37
Number of Products by Stage and Target, H2 2016 39
Number of Products by Stage and Mechanism of Action, H2 2016 41
Number of Products by Stage and Route of Administration, H2 2016 43
Number of Products by Stage and Molecule Type, H2 2016 45
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects, H2 2016 94
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products, H2 2016 95